RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116
Benzinga Newsdesk 21 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains Kymera Therapeutics (NASDAQ:KYMR) with a Sector Perform and raises the price target from $112 to $116.
RBC Capital analyst Brian Abrahams maintains Kymera Therapeutics (NASDAQ:KYMR) with a Sector Perform and raises the price target from $112 to $116.